Trial Profile

COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Colchicine (Primary) ; Ruxolitinib (Primary) ; Secukinumab (Primary) ; Antibacterials; Anticoagulants; Glucocorticoids; Glucocorticoids
Indications COVID 2019 infections; COVID-19 pneumonia
Focus Therapeutic Use
Acronyms COLORIT

Most Recent Events

21 Nov 2022 Status changed from recruiting to completed.
01 Mar 2021 Results comparing efficacy and safety of colchicine in the management of patients with COVID-19 to that without specific anti inflammatory therapy, published in the Kardiologiya
28 May 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com